Illumina, Inc. (ILMN) Earnings Call Analysis
NASDAQ · Healthcare · Diagnostics & Research
Earnings Reports
-
Illumina (ILMN) Q2 2026: Clinical Consumables Up 15% as NovaSeq X Placements Exceed 95 Units
July 31, 2026
-
Illumina (ILMN) Q4 2025: Clinical Consumables Surge 20% as Sequencing Transition Nears Completion
June 15, 2026
-
Illumina (ILMN) Q1 2026: NovaSeq X Placements Surge 60% as Clinical Demand Drives Strategic Upside
May 01, 2026
-
Illumina (ILMN) Q3 2025: NovaSeq X Transition Hits 78% Volume, Unlocking Clinical Growth Leverage
October 31, 2025
-
Illumina (ILMN) Q2 2025: Clinical Sequencing Hits 60% of Consumables, Offsetting Research Weakness
August 01, 2025
-
Illumina (ILMN) Q1 2025: Tariffs Cut $85M From Outlook as China Headwinds Shrink to 4% of Sales
July 05, 2025